Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Lumakras
Biotech
High dose of Cardiff's KRAS drug shows 64% ORR, sending stock up
Cardiff reported deeper tumor responses among the patients receiving the 30-mg dose of the biotech's drug compared to those receiving 20 mg.
Gabrielle Masson
Dec 10, 2024 4:05pm
Merck's early KRAS data suggest combination-friendly safety
Oct 23, 2023 9:45am
Next round of KRAS drugs follow footsteps of Amgen and Mirati
May 4, 2023 6:00am
AACR: Lilly challenges Amgen, Mirati with early KRAS data
Apr 17, 2023 2:30pm
Sanofi sets Revolution back, sending lead asset to the docks
Dec 8, 2022 7:14am
Mirati is once again the subject of takeover talks: report
Nov 23, 2022 11:27am
